Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,695 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K, Iida S. Sunami K, et al. Among authors: matsumoto m. Hematol Oncol. 2023 Aug;41(3):442-452. doi: 10.1002/hon.3105. Epub 2022 Dec 15. Hematol Oncol. 2023. PMID: 36433829 Clinical Trial.
High Th1/Th2 ratio in patients with multiple myeloma.
Ogawara H, Handa H, Yamazaki T, Toda T, Yoshida K, Nishimoto N, Al-ma'Quol WH, Kaneko Y, Matsushima T, Tsukamoto N, Nojima Y, Matsumoto M, Sawamura M, Murakami H. Ogawara H, et al. Among authors: matsumoto m. Leuk Res. 2005 Feb;29(2):135-40. doi: 10.1016/j.leukres.2004.06.003. Leuk Res. 2005. PMID: 15607360
Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan.
Shimada K, Matsue K, Yamamoto K, Murase T, Ichikawa N, Okamoto M, Niitsu N, Kosugi H, Tsukamoto N, Miwa H, Asaoku H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T. Shimada K, et al. Among authors: matsumoto m. J Clin Oncol. 2008 Jul 1;26(19):3189-95. doi: 10.1200/JCO.2007.15.4278. Epub 2008 May 27. J Clin Oncol. 2008. PMID: 18506023
Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.
Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, Niitsu N, Miwa H, Asaoku H, Kosugi H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamamoto K, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T; IVL Study Group in Japan. Shimada K, et al. Among authors: matsumoto m. Cancer Sci. 2010 Jun;101(6):1480-6. doi: 10.1111/j.1349-7006.2010.01555.x. Epub 2010 Mar 6. Cancer Sci. 2010. PMID: 20412122 Free article.
Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.
Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M. Ennishi D, et al. Among authors: matsumoto m. Blood. 2010 Dec 9;116(24):5119-25. doi: 10.1182/blood-2010-06-289231. Epub 2010 Sep 7. Blood. 2010. PMID: 20823454 Free article.
Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases.
Hashimoto Y, Yokohama A, Saitoh A, Nakahashi H, Toyama K, Mitsui T, Koiso H, Saitoh T, Handa H, Uchiumi H, Jinbo T, Murayama K, Matsumoto M, Sawamura M, Karasawa M, Murakami H, Hirato J, Nojima Y, Kojima M, Tsukamoto N. Hashimoto Y, et al. Among authors: matsumoto m. J Clin Exp Hematop. 2013;53(3):197-205. doi: 10.3960/jslrt.53.197. J Clin Exp Hematop. 2013. PMID: 24369221 Free article.
7,695 results